The dyslipidemia treatment developer has filed for a $60m initial public offering that will allow Pfizer, from which it licensed its lead candidate, to exit.

Eye disease therapy developer GenSight Biologics, which had raised almost $78m from investors including Novartis, has withdrawn an IPO expected to raise up to $70m.

The business analytics technology provider, which has raised $590m from investors including Salesforce and WPP, is working with banks to ready itself for an offering.

Intellia Therapeutics, which has raised $85m in under 18 months from backers including Novartis, has signed a collaboration agreement with Regeneron and filed for a $120m IPO.

Aeglea Biotherapeutics, which is developing amino acid-targeted cancer and metabolic disease treatments, had raised $53.5m in VC funding from investors including Novartis and Eli Lilly.

Shareholders of the trading exchange operator, which include several financial services providers, are set to make between $190m and $213m through share sales.

Roche and Novo-backed Corvus Pharmaceuticals priced its IPO at the lower end of its range and raised $70.5m when it floated on Nasdaq yesterday.

Pharmaceutical and healthcare company Hutchison China MediTech, which counts Mitsui as an investor, priced its American depositary shares at $13.50 each.

The Novo and Roche-backed company, which has raised $108m in venture funding, is set to price 4.7 million shares at between $15 and $17.

Mitsui-backed Chi-Med, listed in the UK since 2006, will put the money towards advancing its seven clinical-stage drug candidates.